KRAS and neoplasm: Similar to the development of KRAS G12C inhibitors, the reactivity of KG13 toward the p53 somatic mutant cysteine Y220C provides a precision medicine approach to generate p53 WT activity specifically in tumor cells harboring the p53 Y220C mutation (Fig. 4C, D, and F).